HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: db07-0739v1 57/6/1629    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Belmadani, S. Articles by Matrougui, K. PubMed PubMed Citation Articles by Belmadani, S. Articles by Matrougui, K. Social Bookmarking                What's this?

Elevated Epidermal Growth Factor Receptor Phosphorylation Induces Resistance Artery Dysfunction in Diabetic db/db Mice

¹ Department of Physiology, Louisiana State University Health Sciences Center, New Orleans, Louisiana
² Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, Louisiana
³ Department of Physiology and the Tulane Hypertension and Renal Center of Excellence, Tulane University, New Orleans, Louisiana

Corresponding author: Dr. Khalid Matrougui, Department of Physiology and the Hypertension and Renal Center of Excellence, Tulane University, 1430 Tulane Ave., New Orleans, LA 70112. E-mail: kmatroug{at}tulane.edu

Abbreviations: AGE, advanced glycation end product; EEL, external elastic lamina; EGFR, epidermal growth factor receptor; eNOS, endothelial nitric oxide synthase; IEL, internal elastic lamina; MMP, metalloproteinase; MRA, mesenteric resistance artery; SMC, smooth muscle cell

OBJECTIVE— We previously showed epidermal growth factor receptor (EGFR) transactivation to be key mechanism in the regulation of resistance artery myogenic tone. Type 2 diabetes is associated with microvascular complications. We hypothesized that elevated EGFR phosphorylation contributes to resistance artery dysfunction in type 2 diabetes.

RESEARCH DESIGN AND METHODS AND RESULTS— Diabetic db/db and nondiabetic (control) mice were treated with EGFR inhibitor (AG1478; 10 mg · kg^–1 · day^–1) for 2 weeks. Isolated coronary artery and mesenteric resistance artery (MRA) were mounted in an arteriograph. Pressure-induced myogenic tone was increased in MRA and coronary artery from diabetic mice and normalized by AG1478. Phenylephrine-induced contraction and nitric oxide donor–induced relaxation were similar in all groups. Endothelium-dependent relaxation in response to shear stress and acetylcholine of MRA and coronary artery from diabetic mice was altered and associated with reduced endothelial nitric oxide synthase (eNOS) expression and phosphorylation. Treated diabetic mice with AG1478 improved coronary artery and MRA endothelial function and restored eNOS expression. Immunostaining and Western blot analysis showed increased endothelial and smooth muscle cell EGFR phosphorylation of MRA and coronary artery from diabetic mouse, which was reduced by AG1478. Primary cultured endothelial cells from resistance arteries treated with high glucose for 48 h showed an increase of EGFR phosphorylation associated with eNOS expression and phosphorylation decrease in response to calcium ionophore. Pretreatment of endothelial cells with AG1478 prevented the effect of high glucose.

CONCLUSIONS— This study provides evidence of the role of elevated EGFR phosphorylation in coronary artery and MRA dysfunction in diabetic db/db mice. Therefore, EGFR should be a potential target for overcoming diabetic small artery complications.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?